EUVIMEDEUVIMED entdecken
Open Access

The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials

Elaine Chang iD, Haley Gittleman iD, Chi Song iD, Erik Bloomquist iD, Laura Fernandes iD, Chana Weinstock, Sundeep Agrawal iD, Nicole Gormley, Shenghui Tang, Daniel L Suzman, Laleh Amiri-Kordestani iD, Richard Pazdur und 4 weitere

JNCI Cancer Spectrum · 2025

DOI: 10.1093/jncics/pkaf069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2025. Verfasst von Elaine Chang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Retrospective analyses of studies of IO–containing combinations for advanced renal cell carcinoma (RCC) suggest that depth of response is associated with overall survival but have methodological limitations. We investigated the relationship of week 12 depth of response as a continuous variable with overall survival.

Methods

Pooling data from patients with treatment-naïve advanced RCC enrolled in randomized IO–containing frontline advanced RCC trials submitted to the US Food and Drug Administration that included week 12 imaging assessment, we developed 36-month overall survival prediction models based on week 12 depth of response (reduction from baseline in target lesion diameter) using Cox proportional hazards with natural spline in an IO combination group and a sunitinib group. To avoid guarantee-time bias, only patients in follow-up at the week 12 scan were included. Overall survival was defined from the week 12 imaging date.

Results

Among the 4 trials that met our inclusion criteria, 1364 patients in the IO combination group and 1267 patients in the sunitinib group had week 12 imaging. Depth of response and 36-month overall survival were correlated throughout the entire range of depth of response in both treatment groups, with no plateau in overall survival as depth of response approached complete response. Across this range, estimated 36-month overall survival was higher in the IO combination group.

Conclusions

Deeper response was associated with better 36-month overall survival in this pooled exploratory analysis of treatment-naïve patients with advanced RCC treated with IO combination or sunitinib. Further work characterizing the relationship between depth of response and overall survival at the trial level may advance understanding of the utility of depth of response as a pharmacodynamic response biomarker or early endpoint in signal-seeking trials and to facilitate efficient drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansSunitinibUnited States Food and Drug AdministrationUnited StatesRandomized Controlled Trials as TopicMaleFemaleProportional Hazards ModelsMiddle AgedAgedTreatment Outcome

Substanzen

Sunitinib

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.
  • Statistics, Oncology, Merck & Co, Inc, Rahway, NJ, United States.
  • COTA, New York, NY, United States.
  • Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, United States.
  • Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, United States.
  • Department of Medicine, Harvard Medical School, Boston, MA, United States.

ORCID-Profile: Elaine Chang, Haley Gittleman, Chi Song, Erik Bloomquist, Laura Fernandes, Sundeep Agrawal, Laleh Amiri-Kordestani, Meredith M Regan, Brian I Rini

Zitieren

APA

Chang, E., Gittleman, H., Song, C., Bloomquist, E., Fernandes, L., Weinstock, C., Agrawal, S., Gormley, N., Tang, S., Suzman, D. L., Amiri-Kordestani, L., Pazdur, R., Kluetz, P. G., McDermott, D. F., Regan, M. M., & Rini, B. I. (2025). The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf069

Vancouver

Chang E, Gittleman H, Song C, Bloomquist E, Fernandes L, Weinstock C, et al. The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials. JNCI Cancer Spectrum. 2025. doi:10.1093/jncics/pkaf069

BibTeX
@article{Chang2025,
  author = {Chang, Elaine and Gittleman, Haley and Song, Chi and Bloomquist, Erik and Fernandes, Laura and Weinstock, Chana and Agrawal, Sundeep and Gormley, Nicole and Tang, Shenghui and Suzman, Daniel L and Amiri-Kordestani, Laleh and Pazdur, Richard and Kluetz, Paul G and McDermott, David F and Regan, Meredith M and Rini, Brian I},
  title = {The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials},
  journal = {JNCI Cancer Spectrum},
  year = {2025},
  doi = {10.1093/jncics/pkaf069}
}
Kostenlos starten →